Robust quantitative assay procedures are essential to pharmaceutical quality control. As the foundation of certificates of analysis, they play a critical role in verifying the quality of raw materials, monitoring drug substance manufacturing, and supporting final product release.
Image Credit: Bruker Biospin
This whitepaper explores the development and implementation of such procedures using the Bruker Fourier 80 benchtop NMR spectrometer.
Through examples involving model drug products, it highlights how 1H and 19F qNMR methods offer a balance of simplicity and reliability. These techniques enable efficient, straightforward development of analytical procedures on a compact system specifically designed for quality control labs, while ensuring alignment with regulatory requirements.
Download the full whitepaper here.
About Bruker BioSpin - NMR, EPR and Imaging - Pharma
Welcome to Bruker BioSpin and the world's most comprehensive range of NMR and EPR spectroscopy and preclinical imaging research tools. The Bruker BioSpin Group of companies develop, manufacture and supply technology to research establishments, commercial enterprises and multi-national corporations across countless industries and fields of expertise.
Bruker BioSpin is continuing to revolutionize the design, manufacture and distribution of life science, preclinical, process control and analytical research tools based on magnetic resonance and multimodal imaging technologies. Bruker BioSpin is the worldwide technology and market leader in magnetic resonance technologies (NMR, EPR) and offers the largest portfolio of imaging modalities for preclinical and industrial research under a single brand.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.